Loading company…
Tallac Therapeutics develops antibody drug conjugates designed to activate immune responses against cancer.
Founded in 2018 and based in Burlingame, US, Tallac Therapeutics develops oligonucleotide-based antibody drug conjugates, including Toll-like Receptor Agonist Antibody Conjugates. Its pipeline includes TAC-001, which was in clinical trials. In August 2023, it raised USD 15 mn in venture debt funding from Horizon Technology Finance Corporation.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in